Study Drug and Filgrastim Administration for Each Patient Cohort
| Study Drug and Dose of PEG-rHuMGDF (μg/kg) . | No. Patients . | PEG-rHuMGDF Before Chemotherapy . | Days of PEG-rHuMGDF After Chemotherapy* . | Days of Filgrastim* . | No. of Patients Completing 2 Cycles of Chemotherapy . |
|---|---|---|---|---|---|
| Placebo | 10 | No | 0 | 12 (9-18) | 10 |
| 0.03 | 3 | Yes | 20 | 16 (11-19) | 2 |
| 0.1 | 3 | Yes | 20 | 12 (10-13) | 2 |
| 0.3 | 3 | Yes | 17 (15-20) | 10 (10-13) | 2 |
| 1.0 | 2 | Yes | 11, 20 | 11, 15 | 0 |
| 1.0 | 6 | No | 17 (15-19) | 14 (12-16) | 6 |
| 1.0 | 3 | No | 7 | 11 (10-21) | 3 |
| 3.0 | 7 | No | 7 | 10 (9-17) | 6 |
| 5.0 | 4 | No | 7 | 11 (10-12) | 4 |
| Study Drug and Dose of PEG-rHuMGDF (μg/kg) . | No. Patients . | PEG-rHuMGDF Before Chemotherapy . | Days of PEG-rHuMGDF After Chemotherapy* . | Days of Filgrastim* . | No. of Patients Completing 2 Cycles of Chemotherapy . |
|---|---|---|---|---|---|
| Placebo | 10 | No | 0 | 12 (9-18) | 10 |
| 0.03 | 3 | Yes | 20 | 16 (11-19) | 2 |
| 0.1 | 3 | Yes | 20 | 12 (10-13) | 2 |
| 0.3 | 3 | Yes | 17 (15-20) | 10 (10-13) | 2 |
| 1.0 | 2 | Yes | 11, 20 | 11, 15 | 0 |
| 1.0 | 6 | No | 17 (15-19) | 14 (12-16) | 6 |
| 1.0 | 3 | No | 7 | 11 (10-21) | 3 |
| 3.0 | 7 | No | 7 | 10 (9-17) | 6 |
| 5.0 | 4 | No | 7 | 11 (10-12) | 4 |
Median (range); when no range is given, patients received the stated duration.